MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
LUPI

LUPIN.NS

Lupin Limited

$2370
12.2
 (0.52%)
Exchange:  NSE
Market Cap:  1.084T
Shares Outstanding:  455.288M
Delayed data
Calculate LUPIN.NS Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – Specialty & Generic
   
CEO:  Vinita D. Gupta
Full Time Employees:  19210
Address: 
Kalpataru Inspire
Mumbai
400055
IN
Website:  https://www.lupin.com
Lupin Limited is a pharmaceutical firm dedicated to the creation, manufacturing, commercialization, and distribution of a wide array of branded and generic medications, biotechnology items, and active pharmaceutical ingredients (APIs). Its comprehensive product portfolio addresses diverse therapeutic categories, including cardiovascular health, diabetes management, asthma, pediatric care, central nervous system disorders, gastrointestinal issues, anti-infectives, nonsteroidal anti-inflammatory drug (NSAID) therapy, respiratory ailments, women’s health, and anti-tuberculosis treatments. Beyond its primary offerings, Lupin also supplies biosimilars and over-the-counter (OTC) medicines, alongside specialized pharmaceutical products. The company actively pursues drug discovery and development initiatives focused on oncology, immunology, and metabolic disorders, complementing these efforts with bio-clinical research. Lupin Limited maintains an extensive operational network comprising 18 laboratories, 280 LupiMitra collection centers, and 450 pick-up points. Its global presence extends across numerous countries, such as India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. Originally named Lupin Chemicals Limited, the company adopted its current identity, Lupin Limited, in 2001 following its merger with Lupin Laboratories Limited. Established in 1968, Lupin Limited is based in Mumbai, India.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202420252026
Revenue200,108,200227,079,000279,580,300
Gross Profit128,991,800153,268,600147,945,500
EBITDA36,272,20050,506,70085,695,300
Operating Income77,797,20094,801,00068,970,400
Net Income19,144,80032,816,20053,328,400

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202420252026
Total Assets239,971,800292,048,800383,648,300
Total Liabilities96,237,300119,105,300158,514,600
Total Stockholders Equity142,902,900172,035,000224,482,700
Total Debt29,217,70054,477,70066,161,800
Cash and Cash Equivalents11,876,00015,436,90056,529,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202420252026
Operating Cash Flow36,483,60029,999,40071,899,000
Capital Expenditure-9,289,000-16,824,300-20,548,500
Free Cash Flow27,194,60013,175,10051,350,500
Net Income24,222,70032,816,20053,328,400
Net Change in Cash-2,480,5005,599,30028,976,600

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2029Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)316,581,172.535Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)374,358,715.819Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)343,823,247.450Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)58,541,036.442Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)69,225,049.139Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)63,578,541.634Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)49,330,446.500Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)61,344,545.544Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)54,995,086.667Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)64,635,874.677Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)76,432,223.832Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)70,197,845.802Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)120.080Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)133.940Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)107.710Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)18Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)16Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
3.86
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
20.15
?Enterprise Value
 (TTM)
: 
1.085T  ?EV/FCF
 (TTM)
: 
46.59
?Dividend Yield
 (TTM)
: 
0.01  ?Payout Ratio
 (TTM)
: 
0.1
?ROE
 (TTM)
: 
0.28  ?ROIC
 (TTM)
: 
0.23
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.29
?P/B
 (TTM)
: 
4.79  ?Current Ratio
 (TTM)
: 
1.9

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
2,032.58Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about LUPIN.NS valuation

Is Lupin Limited (LUPIN.NS) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Lupin Limited (LUPIN.NS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is LUPIN.NS a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether LUPIN.NS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is LUPIN.NS’s P/E ratio?

You can see LUPIN.NS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for LUPIN.NS?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is LUPIN.NS a good long-term investment?

Whether LUPIN.NS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

LUPIN.NS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.52
MARKETSnap

Trading Metrics:

Open: 2362   Previous Close: 2357.8
Day Low: 2360   Day High: 2395
Year Low: 1836.8   Year High: 2494
Price Avg 50: 2298.82   Price Avg 200: 2171.15
Volume: 789822   Average Volume: 1.201M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
03-06-2026 04:00
Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets
29-05-2026 13:00
Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read